SEC Form 4 · accession 0001437749-26-021611
Moleculin Biotech, Inc. · MBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Walter V Klemp
Officer — CEO and President · Director
Period of report
Jun 20, 2026
Accepted (ET)
Jun 24, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001659617
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 20, 2026 | M | 150 | — | A | 30,765 | D | |
| Common StockF2 | Jun 20, 2026 | F | 37 | $2.88 | D | 30,728 | D | |
| Common StockF1 | Jun 22, 2026 | M | 360 | — | A | 31,088 | D | |
| Common StockF2 | Jun 22, 2026 | F | 88 | $3.12 | D | 31,007 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF5,F1,F3 | — | Jun 20, 2026 | M | 150 | D | — | — | Common Stock | 150 | 326,696 | D |
| Restricted Stock UnitsF5,F1,F4 | — | Jun 22, 2026 | M | 360 | D | — | — | Common Stock | 360 | 326,336 | D |
Explanation of responses
- F1Restricted stock units convert into common stock on a one-for-one basis.
- F2Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
- F3On June 20, 2022, the reporting person was granted 600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
- F4On June 22, 2023, the reporting person was granted 1,439 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
- F5Includes 250,002 shares of common stock underlying Series E warrants to purchase common stock.